share_log

Barrington Research Maintains Outperform on Haemonetics, Maintains $108 Price Target

Benzinga ·  Sep 23 22:53  · Ratings

Barrington Research analyst Michael Petusky maintains Haemonetics (NYSE:HAE) with a Outperform and maintains $108 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment